661 related articles for article (PubMed ID: 29145879)
1. Allogeneic mesenchymal stem cell as induction therapy to prevent both delayed graft function and acute rejection in deceased donor renal transplantation: study protocol for a randomized controlled trial.
Sun Q; Hong L; Huang Z; Na N; Hua X; Peng Y; Zhao M; Cao R; Sun Q
Trials; 2017 Nov; 18(1):545. PubMed ID: 29145879
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial.
Sun Q; Huang Z; Han F; Zhao M; Cao R; Zhao D; Hong L; Na N; Li H; Miao B; Hu J; Meng F; Peng Y; Sun Q
J Transl Med; 2018 Mar; 16(1):52. PubMed ID: 29514693
[TBL] [Abstract][Full Text] [Related]
3. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.
Tan J; Wu W; Xu X; Liao L; Zheng F; Messinger S; Sun X; Chen J; Yang S; Cai J; Gao X; Pileggi A; Ricordi C
JAMA; 2012 Mar; 307(11):1169-77. PubMed ID: 22436957
[TBL] [Abstract][Full Text] [Related]
4. Effects of cyclosporine A pretreatment of deceased organ donors on kidney graft function (Cis-A-rein): study protocol for a randomized controlled trial.
Orban JC; Fontaine E; Cassuto E; Baumstarck K; Leone M; Constantin JM; Ichai C;
Trials; 2018 Apr; 19(1):231. PubMed ID: 29665840
[TBL] [Abstract][Full Text] [Related]
5. Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study.
Reinders ME; Dreyer GJ; Bank JR; Roelofs H; Heidt S; Roelen DL; Zandvliet ML; Huurman VA; Fibbe WE; van Kooten C; Claas FH; Rabelink TJ; de Fijter JW
J Transl Med; 2015 Nov; 13():344. PubMed ID: 26537851
[TBL] [Abstract][Full Text] [Related]
6. Induction therapy by anti-thymocyte globulin (rabbit) versus basiliximab in deceased donor renal transplants and the effect on delayed graft function and outcomes.
Foster CE; Weng RR; Piper M; Laugenou K; Ichii H; Lakey J; Malinoski D
Transplant Proc; 2012 Jan; 44(1):164-6. PubMed ID: 22310605
[TBL] [Abstract][Full Text] [Related]
7. Marrow Mesenchymal Stem Cells Effectively Reduce Histologic Changes in a Rat Model of Chronic Renal Allograft Rejection.
Yu P; Wang Z; Liu Y; Xiao Z; Guo Y; Li M; Zhao M
Transplant Proc; 2017 Nov; 49(9):2194-2203. PubMed ID: 29149982
[TBL] [Abstract][Full Text] [Related]
8. A double-blind randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial.
Kassimatis T; Qasem A; Douiri A; Ryan EG; Rebollo-Mesa I; Nichols LL; Greenlaw R; Olsburgh J; Smith RA; Sacks SH; Drage M
Trials; 2017 Jun; 18(1):255. PubMed ID: 28587616
[TBL] [Abstract][Full Text] [Related]
9. The 37-year kidney transplantation experience at Siriraj Hospital.
Premasathian N; Vongwiwatana A; Taweemonkongsap T; Amornvesukit T; Limsrichamrern S; Jitpraphai S; Kositamongkol P; Mahawithitwong P; Sritippayawan S; Chanchairujira T; Nualyong C; Vareesangthip K; Vasuvattakul S; Sirivatanauksorn Y
Clin Transpl; 2010; ():141-8. PubMed ID: 21696037
[TBL] [Abstract][Full Text] [Related]
10. The risk of allograft failure and the survival benefit of kidney transplantation are complicated by delayed graft function.
Gill J; Dong J; Rose C; Gill JS
Kidney Int; 2016 Jun; 89(6):1331-6. PubMed ID: 27165823
[TBL] [Abstract][Full Text] [Related]
11. Association Between Duration of Delayed Graft Function, Acute Rejection, and Allograft Outcome After Deceased Donor Kidney Transplantation.
Lim WH; Johnson DW; Teixeira-Pinto A; Wong G
Transplantation; 2019 Feb; 103(2):412-419. PubMed ID: 29762458
[TBL] [Abstract][Full Text] [Related]
12. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
[TBL] [Abstract][Full Text] [Related]
13. Association of donor inflammation- and apoptosis-related genotypes and delayed allograft function after kidney transplantation.
Israni AK; Li N; Cizman BB; Snyder J; Abrams J; Joffe M; Rebbeck T; Feldman HI
Am J Kidney Dis; 2008 Aug; 52(2):331-9. PubMed ID: 18640487
[TBL] [Abstract][Full Text] [Related]
14. Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction.
Patel SJ; Duhart BT; Krauss AG; Moore LW; Egidi MF; Amiri HS; Gaber LW; Gaber AO
Transplantation; 2008 Jul; 86(2):313-20. PubMed ID: 18645496
[TBL] [Abstract][Full Text] [Related]
15. Predictors and outcomes of delayed graft function after living-donor kidney transplantation.
Redfield RR; Scalea JR; Zens TJ; Muth B; Kaufman DB; Djamali A; Astor BC; Mohamed M
Transpl Int; 2016 Jan; 29(1):81-7. PubMed ID: 26432507
[TBL] [Abstract][Full Text] [Related]
16. Synergistic impact of pre-sensitization and delayed graft function on allograft rejection in deceased donor kidney transplantation.
Lee H; Park Y; Ban TH; Song SH; Song SH; Yang J; Ahn C; Yang CW; Chung BH;
Sci Rep; 2021 Aug; 11(1):16095. PubMed ID: 34373479
[TBL] [Abstract][Full Text] [Related]
17. Validating Early Post-Transplant Outcomes Reported for Recipients of Deceased Donor Kidney Transplants.
Potluri VS; Parikh CR; Hall IE; Ficek J; Doshi MD; Butrymowicz I; Weng FL; Schröppel B; Thiessen-Philbrook H; Reese PP
Clin J Am Soc Nephrol; 2016 Feb; 11(2):324-31. PubMed ID: 26668026
[TBL] [Abstract][Full Text] [Related]
18. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
Albano L; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Blanc AS; Di Giambattista F; Dantal J;
Transplantation; 2009 Jul; 88(1):69-76. PubMed ID: 19584683
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients.
Jordan SC; Choi J; Aubert O; Haas M; Loupy A; Huang E; Peng A; Kim I; Louie S; Ammerman N; Najjar R; Puliyanda D; Vo A
Am J Transplant; 2018 Dec; 18(12):2955-2964. PubMed ID: 29637714
[TBL] [Abstract][Full Text] [Related]
20. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study.
Peng Y; Ke M; Xu L; Liu L; Chen X; Xia W; Li X; Chen Z; Ma J; Liao D; Li G; Fang J; Pan G; Xiang AP
Transplantation; 2013 Jan; 95(1):161-8. PubMed ID: 23263506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
